Meeting
2022 ASCO Annual Meeting
DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade.
Authors
Veronique Debien
Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium
Veronique Debien , Virginie ADAM , Rafael Caparica , Debora Fumagalli , Chloé Velghe , Julie Gaye , Vanessa Correia De Nobrega , Amal Arahmani , Gabriele Zoppoli , Martine J. Piccart-Gebhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04675827
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS621)
DOI
10.1200/JCO.2022.40.16_suppl.TPS621
Abstract #
TPS621
Poster Bd #
385a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
First Author: Ciara Catherine Maria O'Sullivan
Poster
2021 ASCO Annual Meeting
A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy (JCOG1806: AMATERAS-BC study).
First Author: Tomomi Fujisawa
Poster
2019 ASCO Annual Meeting
Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.
First Author: Luca Gianni
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring